Solid lipid nanoparticles: an oral bioavailability enhancer vehicle

Abstract

The protective effect of SLNs, coupled with their sustained/controlled release properties, prevents drugs/macromolecules from premature degradation and improves their stability in the GIT. An extensive literature survey reveals that direct peroral administration of SLNs improves the BA of drugs by 2- to 25-fold. Overall, the ease of large-scale production, avoidance of organic solvents and improvement of oral BA make SLNs a potential BA enhancer vehicle for various Class II, III and IV drugs.

Nanostructured lipid carriers as a delivery system of biochanin A

“…Hence, the precise determination of the particle size was very important. Usually, particle size less than 300 nm was advisable for the intestinal transport (Haede et al, 2011).…”

“…The second peak appeared at around 5 h after the appearance of first peak; nevertheless, its concentration was appreciably lower than that of the first peak. It was due to release and distribution of NLC from particular organs into systemic circulation (Haede et al, 2011).…”

“…The CLz/F was significantly decreased in the formulation of BCA-NLC (p50.01). This meant a quick reduction of BCA, which may be transferred to various organs of lymphatic systems in the body (Haede et al, 2011). The possible mechanism of NLC uptake was intracellular uptake via the M-cells of Peyer's patches in the gut.…”

“…Solid lipid nanoparticles (SLNs) were developed at the beginning of the 1990s as an alternative carrier system to nanoemulsions, liposomes and polymeric nanoparticles, and attracted great attention by a deal of research groups all over the world (Haede et al, 2011). Compared to traditional carriers, SLN had several advantages, such as good biocompatibility, controlled drug release and improved solubility of drug (Mehnert & Mader, 2001).…”

Ultra high performance liquid chromatography–tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems

“…It is therefore a challenge to formulate an appropriate delivery system that improves its bioavailability and thus its efficacy. To date, lipid nanosystems (LN) seem to be a promising strategy to overcome the limitations associated with certain drug characteristics including low solubility, poor permeability, instability in the gastrointestinal medium, Pglycoprotein efflux and presystemic drug metabolism [2]. Scientific efforts have therefore been employed to design novel delivery systems based on LN for CyA oral administration leading to better alternatives to those currently available on the market, which will be capable of enhancing its oral bioavailability and thus its efficacy [3][4][5].…”